NASDAQ:LOXO Loxo Oncology (LOXO) Stock Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free LOXO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$234.66▼$234.6650-Day Range N/A52-Week Range$101.70▼$234.93Volume400 shsAverage Volume565,561 shsMarket Capitalization$7.18 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Loxo Oncology alerts: Email Address Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Loxo Oncology Stock (NASDAQ:LOXO)Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.Read More Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! LOXO Stock News HeadlinesMarch 25, 2024 | finance.yahoo.comGlobal CLL Therapeutics Market Set to Reach $9.2 Billion by 2032March 11, 2024 | finance.yahoo.comMOMA Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business OfficerApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.February 26, 2024 | benzinga.comDavid M Mott's Net WorthFebruary 8, 2024 | bizjournals.comFoghorn gets $300M plus investment from Lilly under cancer drug partnershipJanuary 18, 2024 | msn.comEli Lilly’s Jaypirca to lead BTK inhibitor market for leukemiaJanuary 10, 2024 | msn.comIron Condor Alert: LLY Stock Could Net 40% In 4 WeeksJanuary 8, 2024 | finance.yahoo.cominsitro Hires Chief Medical Officer to Advance Therapeutic Programs Toward the ClinicApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.January 8, 2024 | markets.businessinsider.comFoghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024December 5, 2023 | msn.comEli Lilly surprised as POINT Biopharma acquisition remains incompleteDecember 4, 2023 | finance.yahoo.comLilly cancer drug cleared by FDA for expanded leukemia, lymphoma useNovember 4, 2023 | finance.yahoo.comEli Lilly and Company (NYSE:LLY) Q3 2023 Earnings Call TranscriptNovember 2, 2023 | finanznachrichten.deFoghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate UpdateNovember 2, 2023 | ca.investing.comCiti continue to see upside to Eli Lilly & Co.'s 'already rich' valuationNovember 2, 2023 | finance.yahoo.comFoghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate UpdateOctober 4, 2023 | msn.comLilly agrees to buy POINT Biopharma for $1.4bnOctober 4, 2023 | msn.comEli Lilly to pay $1.4-billion for cancer-drug maker Point BiopharmaOctober 3, 2023 | thestreet.comPoint Biopharma stock soars on $1.4B takeover bid from Eli LillyOctober 3, 2023 | msn.comPOINT Biopharma (NASDAQ: PNT) Soars After Eli Lilly’s $1.4 Billion AcquisitionOctober 3, 2023 | msn.comEli Lilly to Pay $1.4 Billion for Cancer-Drug Maker Point BiopharmaOctober 3, 2023 | msn.comEli Lilly Acquiring Cancer Therapy Developer For $1.4 Billion—A Nearly 90% PremiumSeptember 26, 2023 | finanznachrichten.deBiocartis Group NV: Biocartis appoints new Medical Advisory Board (MAB) of renowned practice leadersAugust 28, 2023 | finance.yahoo.comPress Release Biocartis Group NV: Biocartis appoints new Medical Advisory Board (MAB) of renowned practice leadersAugust 25, 2023 | benzinga.comPropulsion of Medullary Thyroid Cancer Clinical Trial Pipeline as Novel and Extensive 15+ Therapies Likely to Enter in the Domain | DelveInsightAugust 16, 2023 | msn.comNext-generation study launched via LSUHS partnership to aid rural cancer patientsAugust 10, 2023 | finanznachrichten.deBiocartis Group NV: Biocartis Partners with Lilly to Explore Biomarker Testing for NSCLC Patients using the Idylla PlatformSee More Headlines Receive LOXO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Loxo Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2018Today4/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:LOXO CUSIPN/A CIK1581720 Webwww.loxooncology.com Phone203-653-3880FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-148,870,000.00 Net Margins-43.49% Pretax MarginN/A Return on Equity-16.42% Return on Assets-8.66% Debt Debt-to-Equity RatioN/A Current Ratio3.62 Quick Ratio3.62 Sales & Book Value Annual Sales$21.30 million Price / Sales337.23 Cash FlowN/A Price / Cash FlowN/A Book Value$12.63 per share Price / Book18.58Miscellaneous Outstanding Shares30,610,000Free FloatN/AMarket Cap$7.18 billion OptionableOptionable Beta2.51 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Joshua H. Bilenker (Age 47)Founder, Pres, CEO & Director Ms. Jennifer Burstein M.B.A. CPA (Age 47)Sr. VP of Fin. Mr. Jacob S. Van Naarden (Age 34)Chief Operating Officer Ms. Jennifer L. KronickVP of HRDr. Nisha Nanda (Age 44)Chief Devel. Officer Key CompetitorsCytokineticsNASDAQ:CYTKViking TherapeuticsNASDAQ:VKTXCerevel TherapeuticsNASDAQ:CEREJazz PharmaceuticalsNASDAQ:JAZZElanco Animal HealthNYSE:ELANView All Competitors LOXO Stock Analysis - Frequently Asked Questions How were Loxo Oncology's earnings last quarter? Loxo Oncology Inc (NASDAQ:LOXO) released its quarterly earnings results on Thursday, August, 9th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.15. The biopharmaceutical company had revenue of $42.60 million for the quarter, compared to analysts' expectations of $32.36 million. Loxo Oncology had a negative net margin of 43.49% and a negative trailing twelve-month return on equity of 16.42%. During the same period last year, the business earned ($0.94) EPS. What other stocks do shareholders of Loxo Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Loxo Oncology investors own include Alibaba Group (BABA), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Netflix (NFLX), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD) and Johnson & Johnson (JNJ). This page (NASDAQ:LOXO) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIBiden replacement revealed?Paradigm PressThe “Perfect Storm” for GoldGold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeThe Next Nvidia?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Loxo Oncology Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.